Your browser doesn't support javascript.
loading
Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia.
Feng, Yuan; Shi, Jianguo; Wang, Lili; Zhang, Xia; Tan, Yunlong; Zhao, Jingyuan; Ning, Yuping; Xie, Shiping; Liu, Xuejun; Liu, Qi; Li, Keqing; Wang, Xiaoliang; Li, Lehua; Xu, Xiufeng; Deng, Wei; Luo, Xiaoyan; Wang, Gang.
Afiliação
  • Feng Y; Department of Psychiatry, Beijing Anding Hospital, National Clinical Research Center for Mental Disorders, Capital Medical University, Beijing, China.
  • Shi J; Department of Psychiatry, Xi'an Mental Health Center, Xi'an, China.
  • Wang L; Department of Psychiatry, Tianjin Anding Hospital, Tianjin, China.
  • Zhang X; Department of Psychiatry, Wuxi Mental Health Center, Wuxi, China.
  • Tan Y; Department of Psychiatry, Beijing Huilongguan Hospital, Beijing, China.
  • Zhao J; Department of Psychiatry, Henan Provincial Mental Hospital, Xinxiang, China.
  • Ning Y; Department of Psychiatry, Guangzhou Brain Hospital, Guangzhou, China.
  • Xie S; Department of Psychiatry, Nanjing Brain Hospital, Nanjing, China.
  • Liu X; Department of Psychiatry, Brain Hospital of Hunan Province, Changsha, China.
  • Liu Q; Department of Psychiatry, Sixth Hospital of Peking University, Beijing, China.
  • Li K; Department of Psychiatry, Hebei Mental Health Center, Baoding, China.
  • Wang X; Mental Health Institute, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Li L; Department of Psychiatry, Second Xiangya Hospital of Central South University, Changsha, China.
  • Xu X; Department of Psychiatry, First Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Deng W; Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, China.
  • Luo X; Medical Division, Sumitomo Pharma(Suzhou)Co., Ltd, Beijing, China.
  • Wang G; Department of Psychiatry, Beijing Anding Hospital, National Clinical Research Center for Mental Disorders, Capital Medical University, Beijing, China.
Psychiatry Clin Neurosci ; 74(6): 336-343, 2020 Jun.
Article em En | MEDLINE | ID: mdl-31823444
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Avaliação de Resultados em Cuidados de Saúde / Risperidona / Cloridrato de Lurasidona Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Psychiatry Clin Neurosci Assunto da revista: NEUROLOGIA / PSIQUIATRIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Avaliação de Resultados em Cuidados de Saúde / Risperidona / Cloridrato de Lurasidona Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Psychiatry Clin Neurosci Assunto da revista: NEUROLOGIA / PSIQUIATRIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China